|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 1 | 2018 | Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study) | Vermersch, Patrick; Coles, Alasdair J.; Boyko, Alexey N.; De Seze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; McCombe, Pamela; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 2 | 2018 | Durable Efficacy and Safety With Alemtuzumab in CARE-MS I Patients Switching From SC IFNB-1a: 5-Year Follow-up (TOPAZ Study) | Steingo, Brian; Oreja-Guevara, Celia; Alroughani, Raed; Brassat, David; Boyko, Alexey N.; McCombe, Pamela; VAN WIJMEERSCH, Bart; Margolin, David H.; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; Vermersch, Patrick | Journal Contribution | M |
| 3 | 2018 | Treatment Experiences of Patients with MS: Results From the Global vs MS (TM) Survey | Bass, Ann; VAN WIJMEERSCH, Bart; Boster, Aaron; Mayer, Lori; Mandel, Matt; Sharrock, Kersten; Mitchell, Colin P.; Singer, Barry | Journal Contribution | M |
| 4 | 2018 | Alemtuzumab Provides Durable Efficacy and Safety Over 5 Years After Switching From SC IFNB-1a: Follow-up of Patients From CARE-MS II (TOPAZ Study) | VAN WIJMEERSCH, Bart; Boyko, Alexey N.; Broadley, Simon; Brassat, David; Dive, Dominique; Hupperts, Raymond M. M.; Lycke, Jan; Montalban, Xavier; Sharrack, Basil; Wray, Sibyl; Margolin, David H.; Chung, Luke; Daizadeh, Nadia; Chirieac, Madalina; Wiendl, Heinz | Journal Contribution | M |
| 5 | 2018 | Determinants of MS re-activation after discontinuing therapies | Husin, H.; Wallace, J.; Malpas, C.; Sharmin, S; Horakova, D.; Havrdova, E. Kubala; Izquierdo, G.; Eichau, S.; Prat, A.; Girard, M.; Duquette, P.; Trojano, M.; Grammond, P.; Lugaresi, A.; Onofrj, M.; Ozakbas, S.; Butzkueven, H.; Sola, P.; Ferraro, D.; Alroughani, R.; Grand'Maison, F.; Terzi, M.; Lechner-Scott, J.; Boz, C.; Hupperts, R.; Shaygannejad, V.; Bergamaschi, R.; Pucci, E.; Van Pesch, V.; Hodgkinson, S.; McCombe, P.; Granella, F.; Slee, M.; VAN WIJMEERSCH, Bart; Karabudak, R.; Prevost, J.; Petersen, T.; Spitaleri, D.; Barnett, M.; Solaro, C.; Iuliano, G.; Verheul, F.; Ramo-Tello, C.; Turkoglu, R.; Fernandez Bolanos, R.; Butler, E.; Macdonell, R.; Soysal, A.; Betancur, M. Moreno; Kalincik, T. | Journal Contribution | M |
| 6 | 2018 | Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension | VAN WIJMEERSCH, Bart; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; Jacobs, Alessia; Wiendl, H. | Journal Contribution | M |
| 7 | 2018 | Durable suppression of MRI disease activity and slowing of brain volume loss in alemtuzumab-treated patients with active RRMS: 7-year follow-up of CARE-MS I (TOPAZ Study) | Schippling, S.; Arnold, D.; Barnett, M.; Comi, G.; Laganke, C.; Rovira, A.; Traboulsee, A.; Melanson, M.; Daizadeh, N.; Nakamura, K.; VAN WIJMEERSCH, Bart; Pelletier, D. | Journal Contribution | M |
| 8 | 2018 | Lack of apparent association between lymphocyte repopulation kinetics and autoimmune events in alemtuzumab-treated patients with relapsing-remitting Multiple Sclerosis through 6 years: CARE-MS extension | Wiendl, H.; Carraro, M.; Comi, G.; Izquierdo, G.; Kim, H. J.; Sharrack, B.; Tornatore, C.; Daizadeh, N.; Melanson, M.; JACOBS, Andre; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 9 | 2018 | Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study) | VAN WIJMEERSCH, Bart; Vermersch, P.; Boyko, A.; de Seze, J.; Hartung, H. -P.; Havrdova, E. Kubala; Inshasi, J. Said; McCombe, P.; Montalban, X.; Pozzili, C.; Melanson, M.; Daizadeh, N.; Rodriguez, C.; Selmaj, K. | Journal Contribution | M |
| 10 | 2018 | Long-term Improvement in Clinical Outcomes in Alemtuzumab-Treated RRMS Patients Who Relapsed Between Courses 1 and 2 (CARE-MS I) | Broadley, S.; Wiendl, Heinz; Fernandez, O.; Freedman, M. S.; Izquierdo, G.; Lycke, J.; Pozzilli, C.; Sharrack, B.; Singer, B. A.; Steingo, B.; Vermersch, P.; Wray, S.; VAN WIJMEERSCH, Bart; Ziemssen, T.; Margolin, D. H.; Thangavelu, K.; Boster, A. | Journal Contribution | M |
| 11 | 2018 | No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 12 | 2018 | No correlation between lymphocyte pharmacodynamics and autoimmune adverse events following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis | Wiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; Jacobs, Alessia; Chung, L.; Daizadeh, N.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 13 | 2018 | Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) | VAN WIJMEERSCH, Bart; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M. M.; Lycke, J.; Massacesi, L.; Montalban, X.; Naismith, R. T.; Pandey, K.; Schippling, S.; Vermersch, P.; Chung, L.; Daizadeh, N.; Rodriguez, C. E.; Nakamura, K.; Wiendl, H. | Journal Contribution | M |
| 14 | 2018 | DURABLE CLINICAL EFFICACY OF ALEMTUZUMAB IN PATIENTS WITH ACTIVE RRMS IN THE ABSENCE OF CONTINUOUS TREATMENT: 7-YEAR FOLLOW-UP OF CARE-MS I PATIENTS (TOPAZ STUDY) | McCombe, Pamela; Boyko, Alexey N.; DeSeze, Jerome; Hartung, Hans-Peter; Havrdova, Eva; Inshasi, Jihad Said; Montalban, Xavier; Pozzilli, Carlo; Selmaj, Krzysztof W.; Vermersch, Patrick; Melanson, Maria; Daizadeh, Nadia; Rodriguez, Claudio E.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 15 | 2018 | A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis | Laureys, Guy; Willekens, Barbara; Vanopdenbosch, Ludo; Deryck, Olivier; Selleslag, Dominik; D'Haeseleer, Miguel; De Becker, Ann; Dubois, Benedicte; Dierickx, Daan; Perrotta, Gaetano; De Wilde, Virginie; van Pesch, Vincent; Straetmans, Nicole; Dive, Dominique; Beguin, Yves; VAN WIJMEERSCH, Bart; Theunissen, Koen; Kerre, Tessa; Van de Velde, Ann | Journal Contribution | A1 |
| 16 | 2018 | Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients | MONTES DIAZ, Gwendoline; FRAUSSEN, Judith; VAN WIJMEERSCH, Bart; Hupperts, R.; SOMERS, Veerle | Journal Contribution | A1 |
| 17 | 2018 | Walking endurance and perceived symptom severity after a single maximal exercise test in persons with mild disability because of multiple sclerosis. | MOUMDJIAN, Lousin; GERVASONI, Elisa; VAN HALEWYCK, Florian; OP 'T EIJNDE, Bert; WENS, Inez; VAN GEEL, Fanny; VAN WIJMEERSCH, Bart; FEYS, Peter; VAN ASCH, Paul | Journal Contribution | A1 |
| 18 | 2018 | Improving fatigue in multiple sclerosis by smartphone-supported energy management: The MS TeleCoach feasibility study | D'hooghe, Marie; Van Gassen, Geert; Kos, Daphne; Bouquiaux, Olivier; Cambron, Melissa; Decoo, Danny; Lysandropoulos, Andreas; VAN WIJMEERSCH, Bart; Willekens, Barbara; Penner, Iris-Katharina; Nagels, Guy | Journal Contribution | A1 |
| 19 | 2018 | Twelve Weeks of Medium-Intensity Exercise Therapy Affects the Lipoprotein Profile of Multiple Sclerosis Patients. | JORISSEN, Winde; VANMIERLO, Tim; WENS, Inez; SOMERS, Veerle; VAN WIJMEERSCH, Bart; BOGIE, Jeroen; Remaley, Alan; OP 'T EIJNDE, Bert; HENDRIKS, Jerome | Journal Contribution | A1 |
| 20 | 2018 | Multidisciplinary data infrastructures in multiple sclerosis: Why they are needed and can be done! | PEETERS, Liesbet; van Munster, Caspar E.; VAN WIJMEERSCH, Bart; BRUYNDONCKX, Robin; LAMERS, Ilse; HELLINGS, Niels; POPESCU, Veronica; Thalheim, Christoph; FEYS, Peter | Journal Contribution | A1 |
Loading...
5
0
5
0
false